Interleukin-1 stimulates prostaglandin biosynthesis by human amnion. 1989

R Romero, and S Durum, and C A Dinarello, and E Oyarzun, and J C Hobbins, and M D Mitchell
Dept. of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06510.

The purpose of these studies was to determine if Interleukin-1 (IL-1) alters the rate of prostaglandin biosynthesis by human amnion. Primary monolayer cultures of amnion cells were established from women undergoing elective cesarean section before the onset of labor. Natural purified and recombinant human IL-1 alpha and IL-1 beta were incubated with amnion cells in culture, and prostaglandin E2 (PGE2) biosynthesis was measured by radioimmunoassay in cell-free media. A concentration-dependent increase in PGE2 production by amnion cells occurred in response to natural purified and recombinant IL-1 preparations. No differences in the parameters of the dose-response curves between the two IL-1 gene products could be determined (p greater than 0.05). Indomethacin blocked the effect of IL-1 in prostaglandin biosynthesis by human amnion. Interleukin-1, a fever mediator, could serve as a signal for the initiation of labor in cases of intrauterine or systemic infection.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000650 Amnion The innermost membranous sac that surrounds and protects the developing embryo which is bathed in the AMNIOTIC FLUID. Amnion cells are secretory EPITHELIAL CELLS and contribute to the amniotic fluid. Amniotic Membrane,Amnions,Amniotic Membranes,Membrane, Amniotic,Membranes, Amniotic
D015232 Dinoprostone The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa. PGE2,PGE2alpha,Prostaglandin E2,Prostaglandin E2alpha,PGE2 alpha,Prepidil Gel,Prostaglandin E2 alpha,Prostenon,E2 alpha, Prostaglandin,E2, Prostaglandin,E2alpha, Prostaglandin,Gel, Prepidil,alpha, PGE2,alpha, Prostaglandin E2

Related Publications

R Romero, and S Durum, and C A Dinarello, and E Oyarzun, and J C Hobbins, and M D Mitchell
January 1991, European journal of pharmacology,
R Romero, and S Durum, and C A Dinarello, and E Oyarzun, and J C Hobbins, and M D Mitchell
March 1994, Prostaglandins, leukotrienes, and essential fatty acids,
R Romero, and S Durum, and C A Dinarello, and E Oyarzun, and J C Hobbins, and M D Mitchell
February 1988, Obstetrics and gynecology,
R Romero, and S Durum, and C A Dinarello, and E Oyarzun, and J C Hobbins, and M D Mitchell
December 1993, Prostaglandins, leukotrienes, and essential fatty acids,
R Romero, and S Durum, and C A Dinarello, and E Oyarzun, and J C Hobbins, and M D Mitchell
September 1990, Prostaglandins, leukotrienes, and essential fatty acids,
R Romero, and S Durum, and C A Dinarello, and E Oyarzun, and J C Hobbins, and M D Mitchell
January 1997, Journal of the Society for Gynecologic Investigation,
R Romero, and S Durum, and C A Dinarello, and E Oyarzun, and J C Hobbins, and M D Mitchell
October 1988, British journal of obstetrics and gynaecology,
R Romero, and S Durum, and C A Dinarello, and E Oyarzun, and J C Hobbins, and M D Mitchell
January 1993, Placenta,
R Romero, and S Durum, and C A Dinarello, and E Oyarzun, and J C Hobbins, and M D Mitchell
August 1991, The Journal of clinical endocrinology and metabolism,
R Romero, and S Durum, and C A Dinarello, and E Oyarzun, and J C Hobbins, and M D Mitchell
February 1986, The Journal of clinical investigation,
Copied contents to your clipboard!